EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177 Lu/ 225 Ac treatment in neuroendocrine tumors and metastatic prostate cancer

Habibollah Dadgar, Ali Pashazadeh, Nasim Norouzbeigi, Majid Assadi, Batool Al-Balooshi, Richard P Baum, Akram Al-Ibraheem, Mohamad Haidar, Mohsen Beheshti, Parham Geramifar, Reza Vali, Seyed Mohammadi und 20 weitere

Theranostics · 18.03.2025 · 15 (10) · 4368-4397

DOI: 10.7150/thno.107963 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Theranostics, erschienen am 18.03.2025. Verfasst von Habibollah Dadgar und 31 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Prostatic Neoplasms, Lutetium, Radioisotopes. Die Arbeit wurde bisher 45-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsProstatic NeoplasmsLutetiumRadioisotopesRadiopharmaceuticalsActiniumHumansMaleRadiometryDNA DamageAnimals

Stichwörter der Autor:innen

177Lu225Ac.DNA damageRadiopharmaceutical therapiesdosimetrytheranostics

Substanzen

LutetiumRadioisotopesRadiopharmaceuticalsLutetium-177ActiniumActinium-225

Autor:innen und Institutionen

  • Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran.
  • Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany.
  • The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy (MIRT), Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran.
  • Dubai Nuclear medicine & Molecular imaging Center- Dubai Academic Health corporation- DAHC, United Arab Emirates.
  • CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
  • Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.

Zitieren

APA

Dadgar, H., Pashazadeh, A., Norouzbeigi, N., Assadi, M., Al-Balooshi, B., Baum, R. P., Al-Ibraheem, A., Haidar, M., Beheshti, M., Geramifar, P., Vali, R., Mohammadi, S., Dash, S., Malasani, V., Cimini, A., Ricci, M., Esmail, A. A., Murad, S., Marafi, F., …, & Zaidi, H. (2025). Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177 Lu/ 225 Ac treatment in neuroendocrine tumors and metastatic prostate cancer. Theranostics, 15(10), 4368-4397. https://doi.org/10.7150/thno.107963

Vancouver

Dadgar H, Pashazadeh A, Norouzbeigi N, Assadi M, Al-Balooshi B, Baum RP, et al. Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177 Lu/ 225 Ac treatment in neuroendocrine tumors and metastatic prostate cancer. Theranostics. 2025;15(10):4368-4397. doi:10.7150/thno.107963

BibTeX
@article{Dadgar2025,
  author = {Dadgar, Habibollah and Pashazadeh, Ali and Norouzbeigi, Nasim and Assadi, Majid and Al-Balooshi, Batool and Baum, Richard P and Al-Ibraheem, Akram and Haidar, Mohamad and Beheshti, Mohsen and Geramifar, Parham and Vali, Reza and Mohammadi, Seyed and Dash, Swagat and Malasani, Vindhya and Cimini, Andrea and Ricci, Maria and Esmail, Abdulredha A and Murad, Sarah and Marafi, Fahad and Treglia, Giorgio and Khalaf, Aysar Najeh and Anwar, Farah M and Usmani, Sharjeel and Omar, Yehia and Muhsin, Haider and Tyurin, Igore E and Zakhary, Andrew and Al-Sebaie, Sahar and Cortes, Danny Mena and AlHashim, Maryam and Arabi, Hossein and Zaidi, Habib},
  title = {Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177 Lu/ 225 Ac treatment in neuroendocrine tumors and metastatic prostate cancer},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {10},
  pages = {4368--4397},
  doi = {10.7150/thno.107963}
}
Kostenlos starten →